Regulation of IRF-3-dependent Innate Immunity by the Papain-like Protease Domain of the Severe Acute Respiratory Syndrome Coronavirus
Open accessThe DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV) is a novel coronavirus that causes a highly contagious respiratory disease, SARS, with significant mortality. Although factors contributing to the highly pathogenic nature of SARS-CoV remain poorly understood, it has been reported that SARS-CoV infection does not induce type I interferons (IFNs) in cell culture. However, it is uncertain whether SARS-CoV evades host detection or has evolved mechanisms to counteract innate host defenses. We show here that infection of SARS-CoV triggers a weak IFN response in cultured human lung/bronchial epithelial cells without inducing the phosphorylation of IFN-regulatory factor 3 (IRF-3), a latent cellular transcription factor that is pivotal for type I IFN synthesis. Furthermore, SARS-CoV infection blocked the induction of IFN antiviral activity and the up-regulation of protein expression of a subset of IFN-stimulated genes triggered by double-stranded RNA or an unrelated paramyxovirus. In searching for a SARS-CoV protein capable of counteracting innate immunity, we identified the papain-like protease (PLpro) domain as a potent IFN antagonist. The inhibition of the IFN response does not require the protease activity of PLpro. Rather, PLpro interacts with IRF-3 and inhibits the phosphorylation and nuclear translocation of IRF-3, thereby disrupting the activation of type I IFN responses through either Toll-like receptor 3 or retinoic acid-inducible gene I/melanoma differentiation-associated gene 5 pathways. Our data suggest that regulation of IRF-3-dependent innate antiviral defenses by PLpro may contribute to the establishment of SARS-CoV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(ii) the papain‐like protease domain of CoV‐NL63 binds BECN1 and STING1, thus hindering BECN1‐mediated autophagosome formation and inhibiting IFN production (Devaraj et al, 2007; Chen et al, 2014)”
From Autophagy in major human diseases (2021) · cites this paper as Devaraj et al, 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
Yoneyama, M., Kikuchi, M., Natsukawa, T., Shinobu, N., Imaizumi, T., Miyagishi, M., Taira, K., Akira, S., & Fujita, T. (2004) · Nature Immunology · doi:10.1038/ni1087 · Cited by 3,929
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses
Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., Uematsu, S., Jung, A., Kawai, T., Ishii, K. J., et al. (2006) · Nature · doi:10.1038/nature04734 · Cited by 3,888
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
Seth, R. B., Sun, L., Ea, C.-K., & Chen, Z. J. (2005) · Cell · doi:10.1016/j.cell.2005.08.012 · Cited by 3,329
Self-citationIKKε and TBK1 are essential components of the IRF3 signaling pathway
Fitzgerald, K. A., McWhirter, S. M., Faia, K. L., Rowe, D. C., Latz, E., Golenbock, D. T., Coyle, A. J., Liao, S.-M., & Maniatis, T. (2003) · Nature Immunology · doi:10.1038/ni921 · Cited by 2,676
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction
Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K. J., Takeuchi, O., & Akira, S. (2005) · Nature Immunology · doi:10.1038/ni1243 · Cited by 2,562
5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474
Cited by
Items 101–200 of 413
SARS‐CoV‐2 nucleocapsid suppresses host pyroptosis by blocking Gasdermin D cleavage
Ma, J., Zhu, F., Shao, F., Shao, F., Yu, D., Ma, J., Zhang, X., Li, W., Qian, Y., Zhang, Y., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108249 · Cited by 130
p53 Degradation by a Coronavirus Papain-like Protease Suppresses Type I Interferon Signaling
Yuan, L., Chen, Z., Song, S., Wang, S., Tian, C., Xing, G., Chen, X., Xiao, Z. J., He, F., & Zhang, L. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.619890 · Cited by 122
“DNA constructs containing wild type and mutants of V5-tagged PLP2 and plasmids of IFN- luciferase were previously described (9, 17).”
MethodSelf-citationDeubiquitylating Enzymes in Cancer and Immunity
Ren, J., Yu, P., Liu, S., Li, R., Niu, X., Chen, Y., Zhang, Z., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202303807 · Cited by 134
Mechanisms of Severe Acute Respiratory Syndrome Pathogenesis and Innate Immunomodulation
Frieman, M., & Baric, R. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00015-08 · Cited by 107
“showed that PLP had no effect on the NF- B pathway (27).”
BackgroundTherapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Zhou, Y., Xie, Y., Tang, L., Pu, D., Zhu, Y., Liu, J., & Ma, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00733-x · Cited by 128
Daczkowski, C. M., Dzimianski, J. V., Clasman, J. R., Goodwin, O., Mesecar, A. D., & Pegan, S. D. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.011 · Cited by 116
Evasion of Antiviral Immunity through Sequestering of TBK1/IKKε/IRF3 into Viral Inclusion Bodies
Wu, X., Qi, X., Qu, B., Zhang, Z., Liang, M., Li, C., Cardona, C. J., Li, D., & Xing, Z. (2013) · Journal of Virology · doi:10.1128/jvi.03510-13 · Cited by 114
“24), or target IRF3/7 directly (7), all resulting in the retention of inactive IRF3 in the 352 cytoplasm.”
BackgroundMitochondria: In the Cross Fire of SARS-CoV-2 and Immunity
Burtscher, J., Cappellano, G., Omori, A., Koshiba, T., & Millet, G. P. (2020) · iScience · doi:10.1016/j.isci.2020.101631 · Cited by 120
Hu, T., Zhang, Y. L., Li, L., Wang, K., Chen, S., Chen, J., Ding, J., Jiang, H., & Shen, X. (2009) · Virology · doi:10.1016/j.virol.2009.03.034 · Cited by 108
“…2005, 2006; Lindner et al., 2005, 2007; Ratia et al., 2006; Sulea et al., 2005) and antagonizing type I interferon to counteract innate immunity (Devaraj et al., 2007), 3CLpro plays a major role in processing viral polyproteins and controlling the activities of replication complexes, thus is…”
BackgroundMatthews, K. L., Coleman, C. M., van der Meer, Y., Snijder, E. J., & Frieman, M. B. (2014) · Journal of General Virology · doi:10.1099/vir.0.062059-0 · Cited by 120
“In addition, a positive-control plasmid encoding the SARS-CoV papain-like protease (PLP) was used, that we have reported previously inhibits IFN-b gene induction (Barretto et al., 2006; Devaraj et al., 2007; Frieman et al., 2009; Sun et al., 2012).”
MethodBechill, J., Chen, Z., Brewer, J. W., & Baker, S. C. (2008) · Journal of Virology · doi:10.1128/jvi.00017-08 · Cited by 105
“These strategies include the production of viral proteins that block the signaling pathways used to induce the production of IFN and IFN-stimulated genes (8, 22, 56, 60).”
BackgroundSelf-citationAntiviral activities of ISG20 in positive-strand RNA virus infections
Zhou, Z., Wang, N., Woodson, S. E., Dong, Q., Wang, J., Liang, Y., Rijnbrand, R. C. A., Wei, L., Nichols, J. E., Guo, J., et al. (2010) · Virology · doi:10.1016/j.virol.2010.10.008 · Cited by 107
“The Urbani strain of SARSCoV was provided by L.M. Haynes and T. G. Ksiazek at the Centers for Disease Control and Prevention, Atlanta, GA. SARS-CoV stocks were grown and titrated in Vero E6 cells (Devaraj et al., 2007).”
BackgroundMethodInfluentialSelf-citationWong, H. H., Fung, T. S., Fang, S., Huang, M., Le, M. T., & Liu, D. X. (2017) · Virology · doi:10.1016/j.virol.2017.12.028 · Cited by 104
“For instance, SARS-CoV Papain-like protease (PLpro) attenuates IFN synthesis by abrogating IRF3 phosphorylation and nuclear translocation by physically interacting with IRF3 (Devaraj et al., 2007).”
BackgroundCOVID19 Disease Map, a computational knowledge repository of virus–host interaction mechanisms
Ostaszewski, M., Niarakis, A., Mazein, A., Kuperstein, I., Phair, R. D., Resendiz, A. O., Singh, V., Aghamiri, S. S., Acencio, M. L., Glaab, E., et al. (2021) · Molecular Systems Biology · doi:10.15252/msb.202110387 · Cited by 123
“SARS-CoV-2 impairs this mechanism (Chu et al , 2020), but the exact components are yet to be elucidated (Liao et al , 2005; Devaraj et al , 2007; Frie-man et al , 2007; Li et al , 2016; Bastard et al , 2020).”
Molecular Biology of the SARS-Coronavirus
Lal, S. K. (2010) · Springer eBooks · doi:10.1007/978-3-642-03683-5 · Cited by 103
Kuri, T., Eriksson, K. K., Putics, A., Züst, R., Snijder, E. J., Davidson, A. D., Siddell, S. G., Thiel, V., Ziebuhr, J., & Weber, F. (2011) · Journal of General Virology · doi:10.1099/vir.0.031856-0 · Cited by 101
Antiviral Drug Discovery for the Treatment of COVID-19 Infections
Ng, T. I., Correia, I., Seagal, J., DeGoey, D. A., Schrimpf, M. R., Hardee, D. J., Noey, E. L., & Kati, W. M. (2022) · Viruses · doi:10.3390/v14050961 · Cited by 109
“As a result, PLpro facilitates viral replication in host cells through antagonism of the host antiviral innate immune response [139,140].”
BackgroundZinzula, L., & Tramontano, E. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.10.002 · Cited by 106
“…nsp3 protein, an essential component of the viral replicase complex, interacts with the adaptor STING, impeding its dimerization and activation and disabling the STING essential function of MAVS recruiter to the TBK1-IKK-e complex for IRF-3 phosphorylation (Devaraj et al., 2007; Sun et al., 2012).”
BackgroundActivation of the Chicken Type I Interferon Response by Infectious Bronchitis Coronavirus
Kint, J., Fernandez-Gutierrez, M. M., Maier, H. J., Britton, P., Langereis, M. A., Koumans, J. T. M., Wiegertjes, G. F., & Forlenza, M. (2014) · Journal of Virology · doi:10.1128/jvi.02671-14 · Cited by 111
“Ifn transcription during infection with coronaviruses such as MHV and SARS-CoV generally is low (9, 10, 12, 13, 49) and was shown to be dependent on cell type and virus strain (50).”
BackgroundPEDV nsp16 negatively regulates innate immunity to promote viral proliferation
Shi, P., Su, Y., Li, R., Liang, Z., Dong, S., & Huang, J. (2019) · Virus Research · doi:10.1016/j.virusres.2019.03.005 · Cited by 98
“The pathogenesis of these viruses might be related to the inefficient detection by the first line of antiviral response mediated by interferon (Rose et al., 2010; Devaraj et al., 2007; Li et al., 2010; Zhao et al., 2011).”
BackgroundNovel Influenza Virus NS1 Antagonists Block Replication and Restore Innate Immune Function
Basu, D., Walkiewicz, M. P., Frieman, M. B., Baric, R. S., Auble, D., & Engel, D. A. (2008) · Journal of Virology · doi:10.1128/jvi.01805-08 · Cited by 106
“Furthermore, our experiments showed that the compounds did not restore IFN- induction that had been inhibited by the SARSCoV PLP protein (Fig.”
MethodInfluentialPapain-Like Protease (PLpro) Inhibitory Effects of Cinnamic Amides from Tribulus terrestris Fruits
Song, Y. H., Kim, D. W., Long, M. J. C., Yuk, H. J., Wang, Y., Zhuang, N., Lee, K. H., Jeon, K. S., & Park, K. H. (2014) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b14-00026 · Cited by 92
Message in a bottle: lessons learned from antagonism of STING signalling during RNA virus infection
Maringer, K., & Fernández-Sesma, A. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.08.004 · Cited by 92
Li, H., Zheng, Z., Zhou, P., Zhang, B., Shi, Z., Hu, Q., & Wang, H. (2010) · Journal of General Virology · doi:10.1099/vir.0.025205-0 · Cited by 91
“For example, the PLP domains of human coronavirus, SARS-CoV and mouse hepatitis virus have DUB and IRF-3 antagonism activities (Barretto et al., 2005; Clementz et al., 2010; Devaraj et al., 2007; Frieman et al., 2009; Lindner et al., 2007; Zheng et al., 2008).”
BackgroundKoonpaew, S., Teeravechyan, S., Frantz, P. N., Chailangkarn, T., & Jongkaewwattana, A. (2019) · Frontiers in Veterinary Science · doi:10.3389/fvets.2019.00034 · Cited by 95
“Previous studies showed that the PLpro of the human coronaviruses SARS-CoV and NL63-CoV antagonize innate immune induction of type I IFNs via deubiquitination/deISGylation of NF-κB signaling molecules, inhibition of IRF3 activation and nuclear translocation, and blocking ubiquitination of STING and disrupting its dime…”
BackgroundFrancis, M. E., Goncin, U., Kroeker, A., Swan, C. L., Ralph, R., Lu, Y. W. W., Etzioni, A. L., Falzarano, D., Gerdts, V., Machtaler, S., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009705 · Cited by 92
Lei, J., Mesters, J. R., Drosten, C., Anemüller, S., Ma, Q., & Hilgenfeld, R. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.06.011 · Cited by 94
“In addition, the SARS-CoV PLpro has been shown to have deubiquitinating and interferon antagonism activities, thereby interfering with the host innate immune response (Barretto et al., 2005; Lindner et al., 2005; Devaraj et al., 2007; Frieman et al., 2009).”
BackgroundInfluentialInterferon antagonism by SARS-CoV-2: a functional study using reverse genetics
Schroeder, S., Pott, F., Niemeyer, D., Veith, T., Richter, A. M., Muth, D., Goffinet, C., Müller, M. A., & Drosten, C. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00027-6 · Cited by 95
Skjesol, A., Aamo, T., Hegseth, M. N., Robertsen, B., & Jørgensen, J. B. (2009) · Virus Research · doi:10.1016/j.virusres.2009.03.004 · Cited by 82
Shi, X., Wang, L., Li, X., Zhang, G., Guo, J., Zhao, D. Q., Chai, S., & Deng, R. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.03.004 · Cited by 92
“1, nsp11 could inhibit the Poly(I:C) (a synthetic dsRNA analog)-induced activation of IFN- promoter, which ith p-284 Luc, phRL-TK and pcDNA3.”
BackgroundMethodInfluentialCarlin, A. F., Plummer, E. M., Vizcarra, E. A., Sheets, N., Joo, Y., Tang, W. W., Day, J., Greenbaum, J., Glass, C. K., Diamond, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.054 · Cited by 87
Jauregui, A. R., Savalia, D., Lowry, V. K., Farrell, C. M., & Wathelet, M. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062416 · Cited by 86
“A number of putative IFN antagonists have been identified in the SARS-CoV genome through a variety of screens: nsp1, nsp3, nsp7, nsp15, ORF3a, ORF3b, ORF6, M and NP [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .”
BackgroundStructure and Function of Viral Deubiquitinating Enzymes
Bailey-Elkin, B. A., Knaap, R. C. M., Kikkert, M., & Mark, B. L. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.06.010 · Cited by 85
“This DUB activity has been implicated in the downregulation of cellular innate immune responses [131] , consistent with the observation that SARS-CoV infection prevents IFN-β induction in infected cells [132] .”
BackgroundResultKochi, Y., Kamatani, Y., Kondo, Y., Suzuki, A., Kawakami, E., Hiwa, R., Momozawa, Y., Fujimoto, M., Jinnin, M., Tanaka, Y., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212149 · Cited by 81
The current landscape of coronavirus-host protein–protein interactions
Perrin‐Cocon, L., Diaz, O., Jacquemin, C., Barthel, V., Ogire, E., Ramière, C., André, P., Lotteau, V., & Vidalain, P. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02480-z · Cited by 84
SARS-CoV-2 N Protein Targets TRIM25-Mediated RIG-I Activation to Suppress Innate Immunity
Savellini, G. G., Anichini, G., Gandolfo, C., & Cusi, M. G. (2021) · Viruses · doi:10.3390/v13081439 · Cited by 87
Recent advances in ZBP1-derived PANoptosis against viral infections
Oh, S., & Lee, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148727 · Cited by 84
Suppression of Host Gene Expression by nsp1 Proteins of Group 2 Bat Coronaviruses
Tohya, Y., Narayanan, K., Kamitani, W., Huang, C., Lokugamage, K. G., & Makino, S. (2009) · Journal of Virology · doi:10.1128/jvi.02485-08 · Cited by 79
“In addition to nsp1 (9, 14, 22), past studies showed that nsp3 (4), ORF 3b (10), ORF 6 (6, 10), and N (10) proteins of SARS-CoV have activities to suppress the host innate immune functions.”
BackgroundMatthews, K. L., Schäfer, A., Pham, A. M., & Frieman, M. B. (2014) · Virology Journal · doi:10.1186/s12985-014-0209-9 · Cited by 77
“We, and others have shown that PLpro inhibits IRF3 activation by blocking phosphorylation of IRF3 and subsequent induction of type I IFN gene transcription [16,23].”
InfluentialHuman Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections
Acosta, P. L., Byrne, A. B., Hijano, D. R., & Talarico, L. B. (2020) · Journal of Immunology Research · doi:10.1155/2020/1372494 · Cited by 83
“The papain-like protease (PLPRO) domain of NS protein-3 of SARS-CoV and HCoV-NL63 inhibits the activation of IRF-3 [142, 143].”
Pfefferle, S., Krähling, V., Ditt, V., Grywna, K., Mühlberger, E., & Drosten, C. (2009) · Virology Journal · doi:10.1186/1743-422x-6-131 · Cited by 85
“In concordance with earlier findings, type I interferon was neither induced nor produced by either SARS-CoV variant in our study [50,58-61].”
Niemeyer, D., Mösbauer, K., Klein, E. M., Sieberg, A., Mettelman, R. C., Mielech, A. M., Dijkman, R., Baker, S. C., Drosten, C., & Müller, M. A. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1007296 · Cited by 73
“The likely mechanism for this additional activity has been identified by in-vitro studies to involve binding of ubiquitin or ubiquitin-like modifiers [34, 54, 58].”
BackgroundSelf-citationFrancés-Monerris, A., Hognon, C., Miclot, T., García-Iriepa, C., Iriepa, I., Terenzi, A., Grandemange, S., Barone, G., Marazzi, M., & Monari, A. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00779 · Cited by 74
Wang, G., Chen, G., Zheng, D., Cheng, G., & Tang, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017192 · Cited by 72
“One possible mechanism is that the papain-like protease (PLpro) domain of the nonstructural protein 3 (nsp3) of SCoV can serve as a potent IFN antagonist by inhibiting the phosphorylation and nuclear translocation of IRF3 [30].”
RNA ‐virus proteases counteracting host innate immunity
Lei, J., & Hilgenfeld, R. (2017) · FEBS Letters · doi:10.1002/1873-3468.12827 · Cited by 76
“In addition, the SARS-CoV PL pro +TM or PL pro alone were also reported to bind IRF3 [133, 134] .”
BackgroundThe Role of the Host Ubiquitin System in Promoting Replication of Emergent Viruses
Valerdi, K. M., Hage, A., van Tol, S., Rajsbaum, R., & Giraldo, M. I. (2021) · Viruses · doi:10.3390/v13030369 · Cited by 72
“Some reports indicated that the inhibition of PLpro blocks SARS-CoV and SARS-CoV-2 replication [77,78].”
BackgroundPorcine deltacoronavirus (PDCoV) infection suppresses RIG-I-mediated interferon-β production
Luo, J., Fang, L., Dong, N., Fang, P., Ding, Z., Wang, D., Chen, H., & Xiao, S. (2016) · Virology · doi:10.1016/j.virol.2016.04.025 · Cited by 69
“…with the IFN response in various ways (Roth-Cross et al., 2007; Totura and Baric, 2012; Zhou and Perlman, 2007), and at least eight proteins encoded by SARS-CoV have been identified as IFN antagonists (Devaraj et al., 2007; Kopecky-Bromberg et al., 2007; Siu et al., 2009; Wathelet et al., 2007).”
Kilianski, A., & Baker, S. C. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.11.004 · Cited by 70
Self-citationEdelmann, M. J., & Kessler, B. M. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.08.010 · Cited by 65
“These two actions were suggested to not be attributable to the protease domain of PLpro, although the results obtained with the catalytic mutants used in this study were inconclusive [48].”
ResultMolecular Insights into Small‐Molecule Drug Discovery for SARS‐CoV‐2
Su, H., Zhou, F., Huang, Z., Ma, X., Natarajan, K., Zhang, M., Huang, Y., & Su, H. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202008835 · Cited by 68
Choudhry, N., Zhao, X., Xu, D., Zanin, M., Chen, W., Yang, Z., & Chen, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00626 · Cited by 70
Immune evasion of SARS-CoV-2 from interferon antiviral system
Min, Y., Huang, M., Sun, X., Dèng, F., Wáng, H., & Ning, Y. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.07.023 · Cited by 70
“As for PLpro, besides the protease activity, it may also act as a deubiquitinase (DUB) and a deISGylase that directly remove ubiquitin or ubiquitin-like ISG15 modifications required for multiple signaling protein activation events, crippling innate immune signaling transduction [58–60].”
Clay, C., Donart, N., Fomukong, N., Knight, J. B., Lei, W., Price, L., Hahn, F., Van Westrienen, J., & Harrod, K. S. (2012) · Journal of Virology · doi:10.1128/jvi.06791-11 · Cited by 64
“Several immune-mediated mechanisms of SARS-CoV pathogenesis have been proposed, including antibody-dependent enhancement of infection, immune subversion (13, 15, 21, 30), immune evasion, as well as viral disruption of immune cell function (2, 38, 61).”
BackgroundPotential COVID-19 papain-like protease PL pro inhibitors: repurposing FDA-approved drugs
Kouznetsova, V. L., Zhang, A., Tatineni, M., Miller, M. A., & Tsigelny, I. F. (2020) · PeerJ · doi:10.7717/peerj.9965 · Cited by 72
Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19
Clemente, V., D’Arcy, P., & Bazzaro, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103492 · Cited by 64
The interplay between emerging human coronavirus infections and autophagy
Zhao, Z., Lu, K., Mao, B., Liu, S., Trilling, M., Huang, A., Lu, M., & Lin, Y. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1872353 · Cited by 63
A review of the latest research on M pro targeting SARS-COV inhibitors
Yang, H., & Yang, J. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00066g · Cited by 69
Kepler, T. B., Sample, C. J., Hudak, K. E., Roach, J. M., Haines, A., Walsh, A., & Ramsburg, E. A. (2010) · BMC Genomics · doi:10.1186/1471-2164-11-444 · Cited by 62
“Most pathogenic viruses, including all of the viruses listed above, possess one or more genes that directly antagonize the type-I interferon response [16] [17] [18] [19] , indicating a strong coevolutionary pressure between these viruses and the type-I interferon system.”
BackgroundCOVID-19 : physiopathologie d’une maladie à plusieurs visages
Bonny, V., Maillard, A., Mousseaux, C., Plaçais, L., & Richier, Q. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.05.003 · Cited by 110
“[73] Devaraj SG, Wang N, Chen Z, Chen Z, Tseng M, Barretto N, et al.”
Potent and selective inhibition of pathogenic viruses by engineered ubiquitin variants
Zhang, W., Bailey-Elkin, B. A., Knaap, R. C. M., Khare, B., Dalebout, T. J., Johnson, G. G. R. J., van Kasteren, P. B., McLeish, N. J., Gu, J., He, W., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006372 · Cited by 67
“Strikingly, coronaviral PL pro s also act as vDUBs to suppress host antiviral innate immune responses by targeting cellular Ub-conjugated substrates [9] [10] [11] [12] [13] [14] .”
BackgroundHenderson, J. A., Verma, N., Harris, R. C., Liu, R., & Shen, J. (2020) · The Journal of Chemical Physics · doi:10.1063/5.0020458 · Cited by 60
Mielech, A. M., Deng, X., Chen, Y., Kindler, E., Wheeler, D. L., Mesecar, A. D., Thiel, V., Perlman, S. M., & Baker, S. C. (2015) · Journal of Virology · doi:10.1128/jvi.00338-15 · Cited by 65
Self-citationEarly IFN type I response: Learning from microbial evasion strategies
Coccia, E. M., & Battistini, A. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.03.005 · Cited by 64
“As described above, the SARS-CoV PLP affects the activation of both IRF3 and NF-B not directly, as initially suggested [66, 154] , but by targeting RIG-I, MAVS, TRAF3 [63] and, as more recently reported, STING [64, 65] .”
BackgroundDing, Z., Fang, L., Yuan, S., Zhao, L., Wang, X., Long, S., Wang, M., Wang, D., Foda, M. F., & Xiao, S. (2017) · Oncotarget · doi:10.18632/oncotarget.17912 · Cited by 59
“While nsp1, -3, -7, -14, -15, and -16 from both SARS-CoV and PEDV were found to inhibit IFN production, as was PEDV nsp5, but not SARS-CoV nsp5 [33, 34, [77] [78] [79] [80] [81] [82] .”
MethodMurine Hepatitis Virus nsp14 Exoribonuclease Activity Is Required for Resistance to Innate Immunity
Case, J. B., Li, Y., Elliott, R., Lu, X., Graepel, K. W., Sexton, N. R., Smith, E. C., Weiss, S. R., & Denison, M. R. (2017) · Journal of Virology · doi:10.1128/jvi.01531-17 · Cited by 59
“The nsp3 of severe acute respiratory syndrome coronavirus (SARS-CoV) prevents IRF3 phosphorylation and NF- B signaling (7).”
BackgroundÁlvarez, E. A., DeDiego, M. L., Nieto-Torres, J. L., Jiménez-Guardeño, J. M., Marcos-Villar, L., & Enjuanes, L. (2010) · Virology · doi:10.1016/j.virol.2010.03.015 · Cited by 57
“In a recent report nsp3 has been shown to be an interferon antagonist (Devaraj et al., 2007).”
Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Tong, T. R. S.-W. (2009) · Infectious Disorders - Drug Targets · doi:10.2174/187152609787847659 · Cited by 61
Bosken, Y. K., Cholko, T., Lou, Y., Wu, K., & Chang, C. A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00174 · Cited by 56
Bakadia, B. M., He, F., Souho, T., Lamboni, L., Ullah, M. W., Boni, B. O. O., Ahmed, A. A. Q., Mukole, B. M., & Yang, G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111008 · Cited by 60
Recent Progress in Studies of Arterivirus- and Coronavirus-Host Interactions
Zhong, Y., Tan, Y. W., & Liu, D. X. (2012) · Viruses · doi:10.3390/v4060980 · Cited by 59
“This prevents IRF3 nuclear translocation [121,122], thereby inhibiting the transcription of type I interferons [123].”
BackgroundLiu, N., Zhang, Y., Lei, Y., Wang, R. Y., Zhan, M., Liu, J., An, Y., Zhou, Y., Zhan, J., Yin, F., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02022 · Cited by 55
The Role of Viral Population Diversity in Adaptation of Bovine Coronavirus to New Host Environments
Borucki, M. K., Allen, J., Chen‐Harris, H., Zemla, A. T., Vanier, G., Mabery, S. L., Torres, C., Hullinger, P. J., & Slezak, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052752 · Cited by 54
“The genome regions analyzed included nsp1and nsp3 (genes involved with evasion of the host innate immune response and other functions such viral replication), nsp14 (designated nsp11 in NCBI BCoV Reference Sequence: NC_003045.1; involved with polymerase fidelity), and the spike protein gene (determinant of host range)…”
MethodInteraction between innate immunity and porcine reproductive and respiratory syndrome virus
Sang, Y., Rowland, R. R. R., & Blecha, F. (2011) · Animal Health Research Reviews · doi:10.1017/s1466252311000144 · Cited by 61
Kint, J., Dickhout, A., Kutter, J. S., Maier, H. J., Britton, P., Koumans, J. T. M., Pijlman, G. P., Fros, J. J., Wiegertjes, G. F., & Forlenza, M. (2015) · Journal of Virology · doi:10.1128/jvi.01057-15 · Cited by 53
Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn
Shahgolzari, M., Yavari, A., Arjeini, Y., Miri, S. M., Darabi, A., Nejad, A. S. M., & Keshavarz, M. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101417 · Cited by 55
A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease
Patchett, S., Lv, Z., Rut, W., Békés, M., Drąg, M., Olsen, S. K., & Huang, T. T. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109754 · Cited by 53
ADAR Editing in Viruses: An Evolutionary Force to Reckon with
Piontkivska, H., Wales-McGrath, B. D., Miyamoto, M. M., & Wayne, M. L. (2021) · Genome Biology and Evolution · doi:10.1093/gbe/evab240 · Cited by 55
The Functional Deubiquitinating Enzymes in Control of Innate Antiviral Immunity
Zong, Z., Zhang, Z., Wu, L., Zhang, L., & Zhou, F. (2020) · Advanced Science · doi:10.1002/advs.202002484 · Cited by 54
Li, S., Zhu, Z., Yang, F., Cao, W., Yang, J. P., Ma, C., Zhao, Z., Tian, H. W., Liu, X., Ma, J., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001186 · Cited by 49
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga, E., Lynton‐Pons, E., & Domingo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904686 · Cited by 52
Wang, D., Fan, J., Fang, L., Luo, R., Ouyang, H., Ouyang, C., Zhang, H., Chen, H., Li, K., & Xiao, S. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.08.011 · Cited by 49
“, 2008); the papain-like protease (PLpro) domains of many coronaviruses, such as severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV), human coronavirus NL63 (HCoV-NL63), and mouse hepatitis virus A59 (MHV-A59), have deubiquitinating (DUB) activity that blocks type I interferons (IFNs) induction (Barretto e…”
Self-citationThe “SARS-unique domain” (SUD) of SARS coronavirus is an oligo(G)-binding protein
Tan, J., Kusov, Y., Mutschall, D., Tech, S., Nagarajan, K., Hilgenfeld, R., & Schmidt, C. L. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.081 · Cited by 48
Ahmed-Hassan, H., Sisson, B., Shukla, R. K., Wijewantha, Y., Funderburg, N. T., Li, Z., Hayes, D., Demberg, T., & Liyanage, N. P. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01979 · Cited by 47
“The suppression of IFN responses by SARS-CoV PLpro is due to the inhibition of phosphorylation of IFN-regulatory factor 3 (IRF3) and its subsequent translocation to the nucleus where it enhances IFN gene transcription (267).”
BackgroundZhou, H., Zhao, J., & Perlman, S. (2010) · mBio · doi:10.1128/mbio.00219-10 · Cited by 45
Kuri, T., Zhang, X., Habjan, M., Martínez‐Sobrido, L., García‐Sastre, A., Yuan, Z., & Weber, F. (2009) · Journal of General Virology · doi:10.1099/vir.0.013599-0 · Cited by 49
“For SARS-CoV (and the related mouse hepatitis virus), it was additionally shown that secretion of IFN-b is inhibited in such double-infected cells, despite a clear transcriptional induction (Devaraj et al., 2007; Roth-Cross et al., 2007).”
BackgroundVieira, C. C., Nery, L., Martins, L. D. B. U., Jabour, L. G. P. P., Dias, R. F., & Silva, A. C. S. E. (2020) · Current Drug Targets · doi:10.2174/1389450121666201020154033 · Cited by 52
Nsp1 proteins of group I and SARS coronaviruses share structural and functional similarities
Wang, Y., Shi, H., Rigolet, P., Wu, N., Zhu, L., Xi, X., Vabret, A., Wang, X., & Wang, T. (2010) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2010.05.014 · Cited by 45
“The papain-like protease interacts with IRF-3 and inhibits its phosphorylation and nuclear translocation (Devaraj et al., 2007).”
BackgroundBacterial OTU deubiquitinases regulate substrate ubiquitination upon Legionella infection
Shin, D., Bhattacharya, A., Cheng, Y.-L., Alonso, M. C., Mehdipour, A. R., van der Heden van Noort, G. J., Ovaa, H., Hummer, G., & Dikic, I. (2020) · eLife · doi:10.7554/elife.58277 · Cited by 41
Clasman, J. R., Báez-Santos, Y. M., Mettelman, R. C., O’Brien, A., Baker, S. C., & Mesecar, A. D. (2017) · Scientific Reports · doi:10.1038/srep40292 · Cited by 43
“SARS PLpro is a highly efficient deubiquitinating (DUB) enzyme having the ability to rapidly hydrolyze isopeptide bonds of proteins that are post-translationally modified by cellular ubiquitin-like (Ubl) molecules, such as ubiquitin (Ub) and interferon-stimulating gene 15 (ISG15), which are two key regulators of the i…”
BackgroundSelf-citationSohag, A. A. M., Hannan, M. A., Rahman, S., Hossain, M., Hasan, M., Khan, M. K., Khatun, A., Dash, R., & Uddin, M. J. (2020) · Drug Development Research · doi:10.1002/ddr.21709 · Cited by 46
Glanz, A., Chakravarty, S., Varghese, M., Kottapalli, A., Fan, S., Chakravarti, R., & Chattopadhyay, S. (2021) · Viruses · doi:10.3390/v13040575 · Cited by 47
“The papain-like protease (PLpro) is an important coronavirus enzyme that processes viral polyproteins and promotes viral spread [141].”
BackgroundInfluentialPiotrowski, Y., Hansen, G., van der Zanden, A. L., Snijder, E. J., Gorbalenya, A. E., & Hilgenfeld, R. (2008) · Protein Science · doi:10.1002/pro.15 · Cited by 43
“The PL of SARS-CoV has been shown to block type-I interferon production in the host.(34) The SARS-unique domain”
BackgroundViral OTU Deubiquitinases: A Structural and Functional Comparison
Bailey-Elkin, B. A., van Kasteren, P. B., Snijder, E. J., Kikkert, M., & Mark, B. L. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003894 · Cited by 49
“Interestingly, coronaviruses (which, together with the arteriviruses, belong to the nidovirus order) also encode papain-like proteases targeting both Ub and ISG15 that were shown to inhibit innate immunity [11] [12] [13] [38] [39] [40] [41] [42] but belong to the ubiquitinspecific protease (USP) class of DUBs [6, 43,…”
BackgroundAdegbola, P. I., Semire, B., Fadahunsi, O. S., & Adegbola, A. E. (2021) · VirusDisease · doi:10.1007/s13337-021-00682-7 · Cited by 50
Chaudhary, J. K., Yadav, R., Chaudhary, P. K., Maurya, A., Kant, N., Rugaie, O. A., Haokip, H. R., Yadav, D., Roshan, R., Prasad, R., et al. (2021) · Cells · doi:10.3390/cells10112949 · Cited by 45
“Similarly, NSP3 may interact with IRF3 protein, preventing its dimerization, phosphorylation, and nuclear translocation [102], apart from inhibiting the NF-κB signalling pathway [103], thereby thwarting the antiviral response.”
BackgroundLi, S.-W., Lai, C., Ping, J.-F., Tsai, F., Wan, L., Lin, Y., Kung, S., & Lin, C. (2011) · Journal of General Virology · doi:10.1099/vir.0.028936-0 · Cited by 43
“This study focused on one SARS-CoV protein, PLpro protease, earlier reported to have antagonistic activity in innate immune responses including synthesis of IFNs and cytokines (Devaraj et al., 2007; Frieman et al., 2009).”
BackgroundMethodResultInfluentialPitsillou, E., Liang, J. J., Ververis, K., Hung, A., & Karagiannis, T. C. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.107851 · Cited by 43
Razali, R., Asis, H., & Budiman, C. (2021) · Microorganisms · doi:10.3390/microorganisms9122481 · Cited by 40
“The cleaving process thus releasing nsp1, nsp2, and nsp3 proteins that will assemble and resulting in the generation of a multifunctional, membrane-associated replicase complex on host membranes, initiating replication and transcription of the viral genome [75,83,85].”
BackgroundKoetzner, C. A., Kuo, L., Goebel, S. J., Dean, A. B., Parker, M. M., & Masters, P. S. (2010) · Journal of Virology · doi:10.1128/jvi.00385-10 · Cited by 49
“Finally, the papain-like proteinase (PLP) domain of SARS-CoV nsp3 is also reported to hinder the activation of IRF-3 and NF- B (9, 12, 60).”
Alefishat, E. A., Jelinek, H. F., Mousa, M., Tay, G. K., & AlSafar, H. S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.01.007 · Cited by 44
Metadata
- Authors
- Devaraj, S. G., Wang, N., Chen, Z., Chen, Z., Tseng, M., Barretto, N., Lin, R., Peters, C. J., Tseng, C.-T. K., Baker, S. C., & Li, K.
- Affiliations
- The University of Texas Medical Branch at Galveston (US)
- Loyola University Chicago (US)
- Lady Davis Institute for Medical Research (CA)
- Corresponding author
- Li, Kui
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2007-11
- Volume
- 282
- Issue
- 44
- Pages
- 32208-32221
- ISSN
- 0021-9258 (ISSN-L)
- PMC
- PMC2756044
- OpenAlex
- W190626844
- Cited by
- 411
- References
- 80
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 14 · 2023: 17 · 2022: 37 · 2021: 72 · 2020: 71 · 2019: 9 · 2018: 5 · 2017: 14 · 2016: 9 · 2015: 9 · 2014: 30 · 2013: 18 · 2012: 13
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 4687 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01ai30039-19-0-2)
- National Institute on Drug Abuse (DA-018054, R21DA018054)
- National Institute of Allergy and Infectious Diseases (P01AI060915, AI060915, AI30039, AI-069285, AI 45798, AI057156, N01-AI-030039, U54AI057156, R01AI069285, R01AI045798)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- SARS-CoV, IRF3, papain-like protease, type I interferon, innate immune evasion, interferon antagonism, IRF3 phosphorylation, TLR3, IFN-stimulated genes, lung epithelial cells, viral pathogenesis
- MeSH terms
- Animals, Bronchi, Cell Line, Humans, Immunity, Innate, Interferon Type I, Peptide Hydrolases, Viral Proteins, Protein Structure, Tertiary, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus, Interferon Regulatory Factor-3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.